title: Reversible Pulmonary Arterial Hypertension Associated with Dasatinib for Chronic Myeloid Leukemia.
abstract: We describe two cases of pulmonary arterial hypertension (PAH) that occurred under dasatinib treatment and were resolved after dasatinib discontinuation. Two patients with chronic phase chronic myeloid leukemia (CML) were switched to dasatinib therapy because of hematological progress while receiving imatinib. These patients had New York Heart Association (NYHA) functional class II dyspnea with elevated right ventricular systolic pressure (RVSP), which progressed under dasatinib treatment. After dasatinib treatment was discontinued, subjective symptoms were improved to NYHA functional class I and the follow-up transthoracic Doppler echocardiography showed improved RVSP. Treatment with an alternate tyrosine kinase inhibitor was initiated and had been continued without development of dyspnea or elevation of RVSP. This report suggests that dasatinib can cause the reversible PAH, therefore, routine cardiopulmonary evaluation before and during treatment with dasatinib may be needed in CML patients with clinical manifestations.
authors: Division of Oncology, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, Korea.|Cancer Research Institute, College of Medicine, The Catholic University of Korea, Seoul, Korea.
authors: Ji Hyung
authors: JH
authors: Hong
authors: Cancer Research Institute, College of Medicine, The Catholic University of Korea, Seoul, Korea.|Division of Hematology, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, Korea.
authors: Sung-Eun
authors: SE
authors: Lee
authors: Cancer Research Institute, College of Medicine, The Catholic University of Korea, Seoul, Korea.
authors: Soo Young
authors: SY
authors: Choi
authors: Cancer Research Institute, College of Medicine, The Catholic University of Korea, Seoul, Korea.
authors: Soo-Hyun
authors: SH
authors: Kim
authors: Cancer Research Institute, College of Medicine, The Catholic University of Korea, Seoul, Korea.
authors: Eun-Jung
authors: EJ
authors: Jang
authors: Cancer Research Institute, College of Medicine, The Catholic University of Korea, Seoul, Korea.
authors: Ju-Hee
authors: JH
authors: Bang
authors: Cancer Research Institute, College of Medicine, The Catholic University of Korea, Seoul, Korea.
authors: Jin Eok
authors: JE
authors: Park
authors: Cancer Research Institute, College of Medicine, The Catholic University of Korea, Seoul, Korea.
authors: Hye-Rim
authors: HR
authors: Jeon
authors: Cancer Research Institute, College of Medicine, The Catholic University of Korea, Seoul, Korea.
authors: Yun Jeong
authors: YJ
authors: Oh
authors: Division of Cardiology, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, Korea.
authors: Jeong-Eun
authors: JE
authors: Yi
authors: Division of Cardiology, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, Korea.
authors: Hae Ok
authors: HO
authors: Jung
authors: Division of Cardiology, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, Korea.
authors: Ho Joong
authors: HJ
authors: Youn
authors: Cancer Research Institute, College of Medicine, The Catholic University of Korea, Seoul, Korea.|Division of Hematology, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, Korea.
authors: Dong-Wook
authors: DW
authors: Kim
mesh_terms: D000328:Adult; D000959:Antihypertensive Agents / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use*; D002121:Calcium Channel Blockers / Q000627:therapeutic use; D000069439:Dasatinib / Q000009:adverse effects* / Q000627:therapeutic use*; D004232:Diuretics / Q000627:therapeutic use; D006801:Humans; D006976:Hypertension, Pulmonary / Q000139:chemically induced* / Q000628:therapy; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D000068677:Sildenafil Citrate / Q000627:therapeutic use; D014665:Vasodilator Agents / Q000627:therapeutic use
chemical_list: D000959:Antihypertensive Agents; D000970:Antineoplastic Agents; D002121:Calcium Channel Blockers; D004232:Diuretics; D014665:Vasodilator Agents; D000068677:Sildenafil Citrate; D000069439:Dasatinib
keywords: Chronic myeloid leukemia; Dasatinib; Pulmonary arterial hypertension
references: Bone Marrow Transplant. 2009 Jun;43(12):967-8
references: 19104491
references: Leuk Res. 2009 Jun;33(6):861-4
references: 18986702
references: Am J Respir Crit Care Med. 2010 Nov 1;182(9):1171-7
references: 20581169
references: BMC Pulm Med. 2011;11:30
references: 21605451
references: Eur Respir J. 2011 Jul;38(1):218-20
references: 21719499
references: Int J Hematol. 2011 Oct;94(4):361-71
references: 21901399
references: Leuk Res. 2012 Jan;36(1):e4-6
references: 21890201
references: Circulation. 2012 May 1;125(17):2128-37
references: 22451584
references: Arterioscler Thromb Vasc Biol. 2012 Jun;32(6):1354-65
references: 22516066
references: Am J Respir Crit Care Med. 2006 May 1;173(9):1023-30
references: 16456139
references: Am J Physiol Lung Cell Mol Physiol. 2003 May;284(5):L826-33
references: 12533438
references: Intern Med. 2012;51(17):2337-40
references: 22975544
references: J Clin Oncol. 2007 Sep 1;25(25):3908-14
references: 17761974
references: Am J Respir Crit Care Med. 2008 Jul 1;178(1):81-8
references: 18420966
references: Eur Heart J. 2009 Oct;30(20):2493-537
references: 19713419